Multiple CMTs per patient model enables discovery of carcinoma-specific processes that inform human BRCA. (Left) CMT model. Tissue samples were collected and annotated for each of the 89 samples from 16 canine patients. For study inclusion, each patient was required to provide a minimum of one sample (represented by colored blocks) from each histological group: normal (green), benign (yellow), and malignant (red). Many of the dogs have multiple samples of different tumor histologies. (Right) FREYA framework. We developed the FREYA framework to study tumor development. Using FREYA, we analyzed multiple primary tumors per patient with RNA and mutation profiling and developed a statistical framework to determine differences in gene expression between normal, benign, and malignant samples, and we compared CMT molecular signals to human breast cancer.
